
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
Clinscience, on September 15th signed an investment agreement to acquire 60% of the digital CRO—EXOM Group. Headquartered in Milan, EXOM carries out its activities in the design, supervision, monitoring and management of Clinical Trials based on its own digital eco-system of more than 20 applications unified in the multi-modular platform Genius Suite.
EXOM Group's proprietary Genius Suite system will allow Clinscience to continue its digital transformation and conduct Clinical Trials with a focus on the needs of both Investigators and Patients and ultimately Sponsors.






